Startups
2023
1-10 Mitarbeitende
Avocet Bio GmbHAvocet Bio exemplifies how the next wave of breakthrough innovation can emerge from versatile RNA-targeting platform technologies that integrate molecular biology with data-driven refinement. Our approach combines CRISPR-Cas13 modalities with bioinformatics and AI-guided target selection to accelerate the path from discovery to effective RNA-based medicines.
We are currently seeking investment from private investors, venture capital firms, and other entities to further support and expand our research and development efforts.
We are open to seed rounds to propel our program into first-in-human clinical trials.
We are currently seeking investment from private investors, venture capital firms, and other entities to further support and expand our research and development efforts.
We are open to seed rounds to propel our program into first-in-human clinical trials.
Adresse
Annastraße 27, 37075 Göttingen, Deutschland
Handelsregister
GmbH
HRB206984
Details
Geschäftsmodell
Avocet Bio operates a platform-based business model that leverages enzmye-guided RNA modulation technology to develop RNA-based therapeutics.
Our approach combines proprietary RNA-targeting strategies, smart guide designs, and optimized delivery solutions to create highly needed treatments with high precision and minimal side effects.
We aim to out-license our technology to pharmaceutical partners for late-stage development and commercialization while exploring co-development opportunities. Beyond antivirals, we are expanding our platform into RNA modulation for broader therapeutic applications. Revenue streams include licensing deals, pharma collaborations, and public health funding, ensuring a scalable and impactful business model. We are equally open to M&A deals.
Technologie Beschreibung
By history, we have emerged as a specialist company in the field of antiviral RNA-based therapeutics. The technology is explained on that example but can be adapted to non-virus RNA targets. We are currently securing a high-profile RNA target with unmet medical need.
Our products utilize the CRISPR/Cas13 system to target RNA viruses and degrade their genetic information. Our technology is able to provide broad-spectrum coverage across multiple strains of a RNA virus family, ensuring a robust defense during viral outbreaks. Avocet Bio's modular platform incorporates a smart combination of virus-family-specific guides, a RNA-editing enzyme, and tailored delivery solutions, e.g. available as inhalable formulations.
Our proposed antiviral approach leverages the precise mechanism of action of the CRISPR/Cas13 system. We use an RNA-guided enzyme that targets viral RNA through carefully designed CRISPR RNAs (crRNAs), which bind with complementary sequences to conserved regions within the viral genome, directing the cutting enzyme to these specific sites for targeted RNA cleavage. This precise targeting ensures that only viral RNA is cleaved, leaving human RNA unaffected and minimizing adverse side effects.
The high specificity of the crRNAs differentiates our approach from existing antiviral agents, which typically work by inhibiting viral attachment to host cells or interfering with viral RNA/DNA replication. By focusing directly on the viral RNA, our method effectively halts viral replication and viral protein production.
We utilize messenger RNA (mRNA) to produce the RNA-editing enzyme within the target cell, alongside with crRNAs, by introducing both mRNA transcripts into the infected cell through liposome-directed delivery.Finanzdaten
Gefördert durch
Leipzig, Germany
SPRIND
Weitere Angaben
SDGs (Sustainable Development Goals)